Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 48,911 shares, a decrease of 40.2% from the August 15th total of 81,764 shares. Approximately 1.6% of the company’s shares are short sold. Based on an average daily volume of 45,186 shares, the short-interest ratio is currently 1.1 days.

Analyst Ratings Changes

A number of research firms have recently weighed in on INTS. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. HC Wainwright raised their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Intensity Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Trading Up 1.8%

NASDAQ:INTS traded up $0.07 during mid-day trading on Thursday, reaching $3.88. The company’s stock had a trading volume of 8,261 shares, compared to its average volume of 41,451. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a market cap of $12.65 million, a P/E ratio of -1.09 and a beta of 2.76. The company’s fifty day simple moving average is $4.34 and its two-hundred day simple moving average is $4.90. Intensity Therapeutics has a twelve month low of $3.51 and a twelve month high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, equities analysts predict that Intensity Therapeutics will post -2.64 EPS for the current year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.